Amelioration of IFN-γ and TNF-α-Induced Intestinal Epithelial Barrier Dysfunction by Berberine via Suppression of MLCK-MLC Phosphorylation Signaling Pathway

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Cao, Min ^a   Wang, Pei ^a   Sun, Chunhong ^a   He, Wen ^a   Wang, Fengjun ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BERBERINE; CLAUDIN 1; GAMMA INTERFERON; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN KINASE; OCCLUDIN; PROTEIN ZO1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ELECTRIC RESISTANCE; ENTEROPATHY; HUMAN; HUMAN CELL; INTESTINAL EPITHELIAL BARRIER DYSFUNCTION; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA PERMEABILITY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; BERBERINE; CACO-2 CELLS; EPITHELIAL CELLS; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERFERON-GAMMA; INTESTINAL MUCOSA; MYOSIN LIGHT CHAINS; MYOSIN-LIGHT-CHAIN KINASE; NF-KAPPA B; PERMEABILITY; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877077406     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061944     Document Type: Article

References (56)

1. Turner JR, (2009) Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9: 799-809.
2. Shen L, Weber CR, Raleigh DR, Yu D, Turner JR, (2011) Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol 73: 283-309.
3. Weber CR, (2012) Dynamic properties of the tight junction barrier. Ann NY Acad Sci 1257: 77-84.
4. Suzuki T, (2013) Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci 70: 631-659.
5. McGuckin MA, Eri R, Simms LA, Florin THJ, Radford-Smith G, (2009) Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 15: 100-113.
6. Salim SS, Söderholm JD, (2011) Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 17: 362-381.
7. Martínez C, González-Castro A, Vicario M, Santos J, (2012) Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome. Gut Liver 6: 305-315.
8. Beaurepaire C, Smyth D, McKay DM, (2009) Interferon-γ regulation of intestinal epithelial permeability. J Interf Cytok Res 29: 133-143.
9. Wang F, Graham WV, Wang YM, Witkowski ED, Schwarz BT, et al. (2005) Interferon-γ and tumor necrosis factor-α synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 166: 409-419.
10. Wang F, Schwarz BT, Graham WV, Wang Y, Su L, et al. (2006) IFN-γ-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology 131: 1153-1163.
11. Al-Sadi R, Ye D, Dokladny K, Ma TY, (2008) Mechanism of IL-1β-induced increase in intestinal epithelial tight junction permeability. J Immunol 180: 5653-5661.
12. Suzuki T, Yoshinaga N, Tanabe S, (2011) IL-6 regulates claudin-2 expression and tight junction permeability in intestinal epithelium. J Biol Chem 286: 31263-31271.
13. Weber CR, Raleigh DR, Su L, Shen L, Sullivan EA, et al. (2010) Epithelial myosin light chain kinase activation induces interleukin-13 expression to alter tight junction ion selectivity. J Biol Chem 285: 12037-12046.
14. Rosen MJ, Frey MR, Washington MK, Chaturvedi R, Kuhnhein LA, et al. (2011) STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction. Inflamm Bowel Dis 17: 2224-2234.
15. Schwarz BT, Wang F, Shen L, Clayburgh DR, Su L, et al. (2007) LIGHT signals directly to intestinal epithelia to cause barrier dysfunction via cytoskeletal and endocytic mechanisms. Gastroenterology 132: 2383-2394.
16. Wyatt J, Vogelsang H, Hübl W, Waldhöer T, Lochs H, (1993) Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 341: 1437-1439.
17. Irvine EJ, Marshall JK, (2000) Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology 119: 1740-1744.
18. Clayburgh DR, Shen L, Turner JR, (2004) A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 84: 282-291.
19. Su L, Shen L, Clayburgh DR, Nalle SC, Sullivan EA, et al. (2009) Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 136: 551-563.
20. Kuo CL, Chi CW, Liu TY, (2004) The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 203: 127-137.
21. Boberek JM, Stach J, Good L, (2010) Genetic evidence for inhibition of bacterial division protein FtsZ by berberine. PLoS One 5: e13745.
22. Saha P, Bhattacharjee S, Sarkar A, Manna A, Majumder S, et al. (2011) Berberine chloride mediates its anti-leishmanial activity via differential regulation of the mitogen activated protein kinase pathway in macrophages. PLoS One 6: e18467.
23. Lee IA, Hyun YJ, Kim DH, (2010) Berberine ameliorates TNBS-induced colitis by inhibiting lipid peroxidation, enterobacterial growth and NF-κB activation. Eur J Pharmacol 648: 162-170.
24. Polk DB, Yan F, (2012) Berberine induces caspase-independent cell death in colon tumor cells through activation of apoptosis-inducing factor. PLoS One 7: e36418.
25. Tan W, Li Y, Chen M, Wang Y, (2011) Berberine hydrochloride: anticancer activity and nanoparticulate delivery system. Int J Nanomed 6: 1773-1777.
26. Zhou H, Mineshita S, (2000) The effect of berberine chloride on experimental colitis in rats in vivo and in vitro. J Pharmacol Exp Ther 294: 822-829.
27. Yan F, Wang L, Shi Y, Cao H, Liu L, et al. (2012) Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice. Am J Physiol Gastrointest Liver Physiol 302: G504-G514.
28. Hong T, Yang Z, Lv CF, Zhang Y, (2012) Suppressive effect of berberine on experimental dextran sulfate sodium-induced colitis. Immunopharmacol Immunotoxicol 34: 391-397.
29. Ma X, Jiang Y, Wu A, Chen X, Pi R, et al. (2010) Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. PLoS One 5: e13489.
30. Cui HS, Hayasaka S, Zhang XY, Hayasaka Y, Chi ZL, et al. (2007) Effect of berberine on barrier function in a human retinal pigment epithelial cell line. Jpn J Ophthalmol 51: 64-67.
31. Gu L, Li N, Li Q, Zhang Q, Wang C, et al. (2009) The effect of berberine in vitro on tight junctions in human Caco-2 intestinal epithelial cells. Fitoterapia 80: 241-248.
32. Amasheh M, Fromm A, Krug SM, Amasheh S, Andres S, et al. (2010) TNFα-induced and berberine-antagonized tight junction barrier impairment via tyrosine kinase, Akt and NFκB signaling. J Cell Sci 123: 4145-4155.
33. Liu H, Li M, Wang P, Wang F, (2011) Blockade of hypoxia-inducible factor-1α by YC-1 attenuates interferon-γ and tumor necrosis factor-α-induced intestinal epithelial barrier dysfunction. Cytokine 56: 581-588.
34. Liu H, Wang P, Cao M, Li M, Wang F, (2012) Protective role of oligomycin against intestinal epithelial barrier dysfunction caused by IFN-γ and TNF-α. Cell Physiol Biochem 29: 799-808.
35. Li Q, Zhang Q, Wang M, Zhao S, Ma J, et al. (2008) Interferon-γ and tumor necrosis factor-α disrupt epithelial barrier function by altering lipid composition in membrane microdomains of tight junction. Clin Immunol 126: 67-80.
36. Amasheh M, Grotjohann I, Amasheh S, Fromm A, Söderholm JD, et al. (2009) Regulation of mucosal structure and barrier function in rat colon exposed to tumor necrosis factor alpha and interferon gamma in vitro: A novel model for studying the pathomechanisms of inflammatory bowel disease cytokines. Scand J Gastroenterol 44: 1226-1235.
37. Ma TY, Boivin MA, Ye D, Pedram A, Said HM, (2005) Mechanism of TNF-α modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol 288: G422-G430.
38. Qi H, Wang P, Liu C, Li M, Huang Y, et al. (2011) Involvement of HIF-1α in MLCK-dependent endothelial barrier dysfunction in hypoxia. Cell Physiol Biochem 27: 251-262.
39. Chen C, Wang P, Su Q, Wang S, Wang F, (2012) Myosin light chain kinase mediates intestinal barrier disruption following burn injury. PLoS One 7: e34946.
40. Graham WV, Wang F, Clayburgh DR, Cheng JX, Yoon B, et al. (2006) Tumor necrosis factor-induced long myosin light chain kinase transcription is regulated by differentiation-dependent signaling events. characterization of the human long myosin light chain kinase promoter. J Biol Chem 281: 26205-26215.
41. Ye D, Ma TY, (2008) Cellular and molecular mechanisms that mediate basal and tumor necrosis factor-α induced regulation of myosin light chain kinase gene activity. J Cell Mol Med 12: 1331-1346.
42. Enk R, Ehehalt R, Graham JE, Bierhaus A, Remppis A, et al. (2007) Differential effect of Rhizoma coptidis and its main alkaloid compound berberine on TNF-α induced NFκB translocation in human keratinocytes. J Ethnopharmacol 109: 170-175.
43. Rosenberger P, Khoury J, Kong T, Weissmuller T, Robinson AM, et al. (2007) Identification of vasodilator-stimulated phosphoprotein (VASP) as an HIF-regulated tissue permeability factor during hypoxia. FASEB J 20: 2613-2621.
44. Yeh WL, Lu DY, Lin CJ, Liou HC, Fu WM, (2007) Inhibition of hypoxia-induced increase of blood-brain barrier permeability by YC-1 through the antagonism of HIF-1α accumulation and VEGF expression. Mol Pharmacol 72: 440-449.
45. Feinman R, Deitch EA, Watkins AC, Abungu B, Colorado I, et al. (2010) HIF-1 mediates pathogenic inflammatory responses to intestinal ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 299: G833-G843.
46. Kannan KB, Colorado I, Reino D, Palange DC, Lu Q, et al. (2011) Hypoxia-inducible factor plays a gut-injurious role in intestinal ischemia reperfusion injury. Am J Physiol Gastrointest Liver Physiol 300: G853-G861.
47. Yan J, Zhang Z, Shi H, (2012) HIF-1 is involved in high glucose-induced paracellular permeability of brain endothelial cells. Cell Mol Life Sci 69: 115-128.
48. Lin S, Tsai SC, Lee CC, Wang BW, Liou JY, et al. (2004) Berberine inhibits HIF-1α expression via enhanced proteolysis. Mol Pharmacol 66: 612-619.
49. Hamsa TP, Kuttan G, (2012) Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators. Drug Chem Toxicol 35: 57-70.
50. Li N, Gu L, Qu L, Gong J, Li Q, et al. (2010) Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells. Eur J Pharm Sci 40: 1-8.
51. Gu L, Li N, Gong J, Li Q, Zhu W, et al. (2011) Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia. J Infect Dis 203: 1602-1612.
52. Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, et al. (2004) TNF-α-induced increase in intestinal epithelial tight junction permeability requires NF-κB activation. Am J Physiol Gastrointest Liver Physiol 286: G367-G376.
53. Gramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, et al. (2003) HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112: 645-657.
54. Frede S, Berchner-Pfannschmidt U, Fanrey J, (2007) Regulation of hypoxia-inducible factors during inflammation. Methods Enzymol 435: 405-419.
55. Sumbayev VV, Yasinska I, Oniku AE, Streatfield CL, Gibbs BF, (2012) Involvement of hypoxia-inducible factor-1 in the inflammatory responses of human LAD2 mast cells and basophils. PLoS One 7: e34259.
56. Scharte M, Han X, Bertges DJ, Fink MP, Delude RL, (2003) Cytokines induce HIF-1 DNA binding and the expression of HIF-1-dependent genes in cultured rat enterocytes. Am J Physiol Gastrointest Live Physiol 284: G373-G384.